GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway

Published:2015-01-31 Issue:3 Volume:32 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Liang Fang,Yue Junmin,Wang Junyong,Zhang Lijuan,Fan Rui,Zhang Hao,Zhang Qingsong

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-015-0486-1.pdf

Reference33 articles.

1. Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet. 2009;10:353–8.

2. Narita S, Tsuchiya N, Habuchi T. Treatment for high-risk localized prostate cancer. Nihon Rinsho. 2014;72:2212–6.

3. Ghosh D, Yu H, Tan XF, Lim TK, Zubaidah RM, Tan HT, et al. Identification of key players for colorectal cancer metastasis by iTRAQ quantitative proteomics profiling of isogenic SW480 and SW620 cell lines. J Proteome Res. 2011;10:4373–87.

4. O’Neill PR, Giri L, Karunarathne WK, Patel AK, Venkatesh KV, Gautam N. The structure of dynamic GPCR signaling networks. Wiley Interdiscip Rev Syst Biol Med. 2014;6:115–23.

5. Zhu YB, Xu L, Chen M, Ma HN, Lou F. GPR48 promotes multiple cancer cell proliferation via activation of Wnt signaling. Asian Pac J Cancer Prev. 2013;14:4775–8.

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role and Mechanisms of Tyro3 in Podocyte Biology and Glomerular Disease;Kidney Diseases;2024-07-24

2. LGR4 attenuates MGP expression and suppresses EGFR activation-induced triple-negative breast cancer metastasis;American Journal of Cancer Research;2024

3. Review on Bladder Cancer Diagnosis;Update on Bladder Cancer;2023-12-13

4. LGR4: A New Receptor Member in Endocrine and Metabolic Diseases;Endocrine Reviews;2023-02-15

5. Recent Advances in Orphan GPCRs Research and Therapeutic Potential;GPCRs as Therapeutic Targets;2022-09-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3